Overview

The Opioid Agonist Therapy Program

The CPSS administers the Opioid Agonist Therapy Program (OATP) on behalf of the Community Care Branch of the Ministry of Health

Two major changes were made to CPSS Regulatory Bylaw 19.1  in December 2018 including the addition of buprenorphine/naloxone, and the elimination of approval required to prescribe methadone for the indication of pain. Approval by the CPSS is still required to prescribe opioid agonist therapy (OAT) for addiction. The OAT Standards and Guidelines were also updated to include the newly approved Hospital-Based Temporary Prescribers (HBTP) and Corrections-Based Temporary Prescribers (CBTP).